worldwide silent growing insulin market (estimated to reach 100 billion by 2035) is a testament to the failure of the current anti-diabetic therapeutics currently available on the market. Cardiovascular disease, fatty liver disease, chronic kidney disease, blindness and neuropathy are its devastating complications resulting in enormous costs estimated to be + $450 Billion in the US alone.